Compare Natera Inc. Common Stock (NTRA) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs OneSpan Inc — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while OneSpan Inc trades at $17.52 (market cap $670.71M). The key difference: Natera Inc. Common Stock is far larger — about 85× OneSpan Inc's market cap, and OneSpan Inc pays a 2.86% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and OneSpan Inc for 18 Days on average.
| NTRA | OSPN | |
|---|---|---|
Market Cap | $57.03B | $670.71M |
Volume | 1,131,157 | 364,626 |
Sector | Health | Technology |
52-Week High | $425.64 | $18.42 |
52-Week Low | $179.42 | $10.15 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $56.18B | $639.79M |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
OneSpan (OSPN) trades at $18.20, up 1.96% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with a 73.58% gross margin and consistent earnings beats, though net cash flow turned negative in 2026. Recent product innovation with DigipassONE and positive analyst coverage support the current valuation.
The outlook remains positive given strong profitability metrics and analyst consensus, but investors should monitor cash flow trends and competitive pressures in the cybersecurity sector. The stock's current valuation appears reasonable with a P/E of 10.28, offering potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
